Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM

Phase 2 Active not recruiting 35 enrolled Neurimmune AG Alexion Pharmaceuticals, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 2, single-arm, multicenter study to evaluate the pharmacodynamics and safety of re-treatment with ALXN2220 in previous participants of Study NI006-101.

Timeline

Start: 2025-08-28
Primary completion: 2026-10-31
Completion: 2026-10-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ALXN2220	Unknown	—	Intravenous

Indications

No indication recorded.